Current Report Filing (8-k)
June 18 2020 - 4:15PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
June 17, 2020
ARMATA
PHARMACEUTICALS, INC.
(Exact name of Registrant as specified in
its charter)
Washington
|
001-37544
|
91-1549568
|
(State or other jurisdiction of incorporation or organization)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
4503 Glencoe Avenue
Marina del Rey, California
|
90292
|
(Address of principal executive offices)
|
(Zip Code)
|
(310) 655-2928
(Registrant’s Telephone number)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of
the Act:
Title of Each Class
|
|
Trading Symbol(s)
|
|
Name of Each Exchange on Which Registered
|
Common Stock
|
|
ARMP
|
|
NYSE American
|
On June 17, 2020, the Company issued a press release announcing
$15 million award from the U.S. Department of Defense (DoD) for development of bacteriophage therapy to treat S. aureus
bacteremia infections. The full text of the press release issued in connection with this announcement is attached as Exhibit 99.1
to this Current Report on Form 8-K and incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 18, 2020
|
Armata Pharmaceuticals, Inc.
|
|
|
|
By:
|
/s/ Steve R. Martin
|
|
Name:
|
Steve R. Martin
|
|
Title:
|
Chief Financial Officer
|
Armata Pharmaceuticals (AMEX:ARMP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Armata Pharmaceuticals (AMEX:ARMP)
Historical Stock Chart
From Sep 2023 to Sep 2024